Biolexis Therapeutics Advances GLP-1 Receptor Activation with AI

Biolexis Therapeutics has confirmed a novel allosteric activation mechanism for the GLP-1 receptor using its AI-driven platform, MolecuLern, announced in a press release. The company achieved this milestone through the cryo-electron microscopy (cryoEM) structure resolution of BLX-7006, a first-in-class oral small-molecule GLP-1 receptor agonist.

The cryoEM structural confirmation validates the predictive capabilities of MolecuLern, which identified BLX-7006 as a novel small molecule capable of allosterically modulating GLP-1 receptor activity. Unlike other oral small-molecule GLP-1 therapies, BLX-7006 is a brand-new chemotype with a unique binding mode.

Biolexis is currently completing the necessary toxicology and manufacturing studies to support human clinical testing of BLX-7006, with plans to initiate first-in-human trials in Q3 2025. This marks a significant step toward providing new therapeutic options for patients with obesity, type 2 diabetes, and metabolic dysfunction.